… sclerosis. Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been …

… OF CD19 IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CAR-T THERAPY Read the interview JON J. VAN ROOD AWARD  to Janaki … TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome …

… is promising, although under investigation. Application of CAR-T regs in autoimmune diseases - Matteo Doglio Matteo Doglio gave updates on ongoing studies for CAR-T regs in SLE, a very promising and rapidly evolving …

… with drug shortages as well as recent developments in CAR-T in BiTE therapies.  We are confident that the programme …

… sclerosis (SSc). Recently, novel cellular therapies (i.e. CAR-T cells, mesenchymal cells) have been successfully adopted in …

… of updated Practice Recommendations for HCT and CAR-T Therapy and the second edition of the EU CAR T-cell Handbook reaffirmed our leadership in harmonising …

… Autoimmune and autoinflammatory complications after CAR-T cell therapy - a joint study on behalf of the EBMT - ADWP, …

… and set limits. With the new treatment of CAR-T and other therapies, and the ever-growing requests for … because this delay means that the proper forms for CAR-T / IEC were not developed in PROMISE, and now we are …

… the privilege of presenting two first-author posters on CAR-T therapy and bispecific antibodies in lymphoma, and one of … advances in hematopoietic stem cell transplantation and CAR-T therapy. The scientific sessions were not only …

… and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma … infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy Kitsada Wudhikarn & Miguel-Angel Perales Get …